The Rise of Automated Insulin Delivery: User Experience and Acceptance Across Age Groups

The evolution of diabetes technology has brought forth the artificial pancreas, a system that combines continuous glucose monitoring, insulin pump, and sophisticated algorithms to automate insulin delivery. These hybrid closed-loop systems represent a significant leap forward, offering the promise of improved glycemic control and reduced daily burden. However, the real-world success of these devices hinges not just on their technical performance but on how different users—from children to older adults—engage with, trust, and ultimately accept them. Understanding the nuanced user experience across age groups is critical for clinicians, device manufacturers, and caregivers to optimize adoption and long-term outcomes.

What Constitutes an Artificial Pancreas System

An artificial pancreas, more accurately termed an automated insulin delivery (AID) system, integrates three core components: a continuous glucose monitor (CGM) that measures interstitial glucose levels every few minutes, an insulin pump that delivers rapid-acting insulin, and a control algorithm that processes CGM data and calculates insulin doses. The algorithm then instructs the pump to adjust basal rates or deliver corrective boluses, aiming to maintain glucose levels within a target range. Modern systems, such as Medtronic's MiniMed 670G/780G, Tandem's Control-IQ, and the open-source Loop system, vary in their level of automation. Some require meal announcements and exercise input, while advanced systems operate with minimal user intervention.

This technology has matured from early investigational devices to commercially available systems with robust clinical trial evidence demonstrating improvements in time-in-range, reductions in hypoglycemia, and lower HbA1c. Yet, user experience is shaped by more than clinical metrics. Device size, alarm fatigue, skin reactions from sensors, and the psychological burden of relying on a machine for life-sustaining therapy all play pivotal roles in acceptance.

Age-Specific Patterns of Acceptance

Children and Adolescents: Enthusiasm Meets Real-World Hurdles

Younger users often embrace AID systems with remarkable openness. For children with type 1 diabetes, these devices can dramatically reduce the constant vigilance required from parents and relieve the child from frequent fingerstick checks. The ability to participate in sports, sleepovers, and school activities with less interruption is a powerful motivator. Studies indicate that children and teens using AID systems experience increased quality of life and less diabetes distress. However, acceptance is not universal. Device size remains a concern; many adolescents prefer smaller, more discreet pumps or even patch pumps that adhere directly to the skin. The requirement for wearing two devices—a pump and a CGM—can feel stigmatizing in social settings. Alarm fatigue is another significant issue; frequent alerts for calibration, sensor errors, or temporary deviations can lead to frustration and even device abandonment. Educational programs that involve the child, parents, and school staff are essential. Gamification elements or mobile apps that engage younger users can further boost adherence. The key is to address the social and emotional aspects of wearing an artificial pancreas, not just the technical training.

Parental involvement also shifts as children grow. Younger children rely heavily on parents for device management, while adolescents seek independence. Systems that allow parents to remotely monitor glucose data via smartphone apps, such as Dexcom Follow, provide a safety net without constant supervision. Balancing autonomy with oversight is a delicate dance that influences acceptance.

Adults: Balancing Convenience and Control

Adults between 25 and 60 years old represent the largest group of AID users, and their experience reflects a wide range of lifestyles, occupations, and attitudes toward technology. Many adults appreciate the reduction in daily decision-making—no more calculating insulin doses for every meal or correction. This cognitive offloading is often cited as the greatest benefit. Improved sleep due to fewer nighttime hypoglycemic events is another strong motivator. However, adults may harbor concerns about device reliability, especially in professional settings or during exercise. Data privacy and the fear of hacking—though largely unfounded—can create hesitancy. The learning curve for new systems is typically shorter for tech-savvy adults, but those less comfortable with smartphones or digital health may struggle. Customizable settings, such as adjustable target glucose ranges and exercise modes, accommodate diverse routines. Ongoing support from certified diabetes care and education specialists (CDCES) greatly enhances confidence. Adults who integrate the device into their daily rhythm—treating it as a tool rather than a constant reminder of their condition—report the highest satisfaction.

Workplace acceptance is also a factor. Professionals in jobs requiring high concentration or physical activity need devices that do not interfere. Many adults report that AID systems actually boost productivity by eliminating the cognitive load of manual insulin adjustments. However, the initial adjustment period can be frustrating, with occasional sensor inaccuracies or pump occlusions. Patient education that sets realistic expectations for these early challenges helps prevent premature abandonment.

Older Adults: Overcoming Barriers with Tailored Support

Older adults (65+ years) with type 1 diabetes often face unique challenges. Age-related declines in dexterity, vision, and cognition can make it difficult to change infusion sets, calibrate sensors, or interpret data. Many older individuals also have coexisting conditions like cardiovascular disease or kidney impairment that complicate diabetes management. Yet, the potential benefits of AID are immense: reduced risk of severe hypoglycemia, improved cognitive function, and greater independence. A study published in Diabetes Technology & Therapeutics found that older adults who used AID systems experienced fewer hypoglycemic events and reported high satisfaction after initial training.

Barriers to uptake include technophobia—a reluctance to rely on a machine for such a critical function—and the physical demands of device maintenance. Simplified interfaces with larger fonts and fewer buttons, voice guidance, or remote caregiver monitoring can bridge the gap. Involving adult children or home health aides in training and ongoing management is often effective. Some older adults prefer devices with longer sensor wear times (up to 14 days) to reduce insertion frequency. The perception of wearing a “medical device” may also be stigmatizing; a discreet design that resembles a smartwatch or small patch can improve acceptance.

Pediatric endocrinologists and geriatric diabetes specialists alike recommend a gradual introduction: start with a CGM alone for several months to build familiarity, then add the pump and algorithm. This stepwise approach reduces overwhelm and allows older users to gain confidence at their own pace. Telehealth follow-ups have also proven valuable for remote troubleshooting and reinforcement.

Cross-Cutting Factors That Shape User Experience

Ease of Use and Training

Across all age groups, the learning curve for AID systems is a critical determinant of acceptance. Devices that require less manual input—such as systems that automatically adjust basal rates and autocorrect for missed boluses—are generally preferred. However, no system is completely hands-off; users must still count carbohydrates for meals, input activity levels, and change sensors and reservoirs. Training that is tailored to the user’s cognitive style and prior experience with diabetes technology significantly improves outcomes. Hands-on sessions with a diabetes educator, followed by a 24/7 helpline, set users up for success. Online video tutorials and peer support groups (such as those on TuDiabetes or various Reddit communities) also help bridge knowledge gaps.

Physical Comfort and Design

The physical burden of wearing multiple devices is often underappreciated. Insulin pumps and CGM transmitters must be attached to the body 24/7, leading to potential skin irritation, interference with clothing, and discomfort during sleep. Younger users are particularly sensitive to device bulk; small, lightweight pumps like the Omnipod DASH/Dash or Tubeless patch pumps are popular. For older adults, larger buttons and easier-to-read screens enhance usability. Adhesive allergies can be a problem; using barrier wipes or switching brands can mitigate reactions. The trend toward longer wear times (CGM sensors lasting 10-14 days) and smaller form factors will continue to improve acceptance.

Reliability and Alarm Management

Reliability is non-negotiable. Any system that malfunctions—whether a sensor drift, pump occlusion, or algorithm error—erodes trust quickly. Users report that frequent alarms for calibrations, sensor failures, or impending hypoglycemia can lead to burnout. Customizable alarm thresholds and the ability to mute non-critical alerts are highly desired. In a 2023 study on alarm fatigue, nearly 40% of AID users reported that too many alarms negatively impacted their quality of life. Manufacturers are responding by offering “silent” alerts or adaptive algorithms that learn individual circadian patterns.

Psychological Readiness and Trust

Trust in the algorithm’s ability to make safe dosing decisions is foundational. Younger users, who have often grown up with smartphones and automation, tend to have higher baseline trust. Older adults may require more time to develop confidence. A 2022 systematic review in Diabetic Medicine noted that “technology acceptance among older adults is heavily influenced by perceptions of usefulness and ease of use, but also by the emotional support provided during adoption.” Peer testimonials from similar-age users can be powerful. Clinicians should assess each patient’s readiness for technology adoption, addressing fears of hypoglycemia or device failure openly. Some clinics use a “shared decision-making” tool that walks patients through the pros and cons.

Demographic and Cultural Considerations

Though age is a primary factor, socioeconomic status, race, and geography also influence acceptance. In the United States, insurance coverage gaps and high out-of-pocket costs remain significant barriers for many families. A study by the Journal of Diabetes Science and Technology found that lower-income populations and minority groups are less likely to start or continue AID therapy, not due to lack of interest but due to financial and logistical obstacles. International variation is also notable: in countries like the UK and Sweden, where public health systems subsidize AID devices, adoption rates are higher. Manufacturers are exploring lower-cost sensors and pumps, but regulatory hurdles persist. Cultural attitudes toward body-worn technology and self-care practices also play a role; tailored outreach materials in multiple languages can help bridge gaps.

Future Directions to Enhance Acceptance

The next generation of AID systems will likely integrate faster-acting insulins, dual-hormone (insulin plus glucagon) approaches, and fully closed-loop operation without meal announcements. Such advances could further reduce user burden, but only if they are designed with the end-user in mind. User-centered design processes that involve patients of all ages in development and testing are essential. Artificial intelligence may help predict and prevent hypoglycemia or hyperglycemia with greater accuracy, potentially reducing alarms. Remote firmware updates, as already seen in the Tandem t:slim X2, mean users can upgrade without replacing hardware.

Efforts to improve skin tolerability, reduce sensor warm-up time, and extend infusion set longevity will continue to address physical barriers. On the training front, immersive virtual reality simulations for children and interactive online modules for older adults could standardize high-quality education. Finally, social support platforms and community-based programs that pair new users with experienced peers will foster a sense of belonging and shared learning.

Clinical Implications for Practitioners

Clinicians should proactively discuss AID options with all age-appropriate candidates, not just those who express interest. Use validated readiness assessment tools, such as the Technophilia/Technophobia scale, to gauge comfort levels. For children, involve the entire family in decision-making and address school-based concerns. For older adults, ensure that vision, hearing, and cognitive function are evaluated, and provide written instructions with large print. In all cases, schedule frequent follow-ups during the first three months to address emerging issues. The goal is not just glycemic improvement but also user satisfaction—because a system that is not used is worthless.

Conclusion

Artificial pancreas devices have transformed diabetes care, but their real-world impact depends on acceptance across diverse age groups. Children and adolescents thrive when devices are socially acceptable and emotionally supportive; adults benefit from reliability and control; older adults need tailored training and caregiver integration. Common threads—ease of use, minimal alarms, physical comfort, and trust—cut across ages. As technology evolves and costs decrease, the focus must remain on human factors. By addressing these with empathy and evidence, we can ensure that more people with diabetes experience the freedom that an automated insulin delivery system can provide. Continued collaboration between device manufacturers, healthcare providers, and the diabetes community will drive the next wave of innovation that truly meets the needs of every user.

For further reading on user experiences with closed-loop systems, refer to JDRF's guide to the artificial pancreas and the UK Diabetes UK patient information on hybrid closed-loop systems.